Stable Angina: The best Stable Angina: The best timing of coronary timing of coronary angiography and the role angiography and the role of further of further investigations on investigations on myocardial ischemia myocardial ischemia still need to be defined still need to be defined Eliano Pio Navarese, MD, PhD Nicolaus Copernicus University, Poland SIRIO MEDICINE network
20
Embed
Eliano Pio Navarese, MD, PhD Nicolaus Copernicus University, Poland SIRIO MEDICINE network
Stable Angina: The best timing of coronary angiography and the role of further investigations on myocardial ischemia still need to be defined. Eliano Pio Navarese, MD, PhD Nicolaus Copernicus University, Poland SIRIO MEDICINE network. Very Early vs delayed PCI in NSTE-ACS. Background. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Stable Angina: The best Stable Angina: The best timing of coronary timing of coronary
angiography and the role angiography and the role of further investigations of further investigations onon myocardial ischemia myocardial ischemia still need to be defined still need to be defined
Eliano Pio Navarese, MD, PhDNicolaus Copernicus University, Poland
SIRIO MEDICINE network
Very Early vs delayed PCI in
NSTE-ACS
Navarese, Ann Intern Med 2013
In NSTE-ACS the superiority of coronary angiography/PCI vs a conservative medical treatment has been shown.
In NSTE-ACS a very early invasive approach (≤ 24 hours) is not proven to be superior to an delayed approach (>24 hour).
Trials showed no advantage of coronary angiography/PCI
vs medical therapy in stable
coronary artery disease (CAD).
Which is the best timing of angiography in stable CAD?
Background
PCI vs medical therapy Stepwise diagnostic approach to CAD
Guidelines require a Bayesian approach to diagnosis, which uses the results of diagnostic tests along with clinicians’ initial estimates of the disease, termed pre-test probability (PTP).
ESC guidelines, EHJ 2013
ESC guidelines, EHJ 2013
ESC guidelines, EHJ 2013
COURAGE trial: COURAGE trial: Survival Free of Death from Any Cause and Myocardial Infarction
Number at RiskMedical Therapy 1138 1017 959 834 638 408 192 30PCI 1149 1013 952 833 637 417 200 35
Years0 1 2 3 4 5 6
0.0
0.5
0.6
0.7
0.8
0.9
1.0
PCI + OMT
Optimal Medical Therapy (OMT)
Hazard ratio: 1.0595% CI (0.87-1.27)P = 0.62
7
Boden, et al. N Engl J Med 2007
Bangalore, Circulation 2012
Issues of the Courage trial
1) Selection bias (randomization after cardiac catheterization)
2) No sufficient threshold for ischemia (lower risk)
3) No use of contemporary techniques such as FFR and minimal use of DES
Rossini, Am J Cardiovasc Dis. 2013
Hachamovitch et al. Circ 1998;
Card
iac
Death
Rate
(%
)
0% 1-5% 5-10% 11-20% >20%*p < 0.0001 % Total Myocardium Ischemic†10,627 Consecutive patients followed 1.9 + 0.6 years.
*
§
Primary endpoint: % with ischemia reduction ≥ 5% myocardium (N=314)
19.8%
p=0.00433.3%
Isch
em
ia r
ed
ucti
on
≥ 5
%
COURAGE nuclear substudy IICOURAGE nuclear substudy II